Background: Even though statin therapy was proved to improve clinical outcomes and reduce the incidence of major adverse cardiac events (MACE) in acute coronary syndrome (ACS), little is known about the effect of statin therapy in acute myocardial infarction (AMI) with non-diabetic renal insufficiency. Methods: We analyzed 1,257 AMI patients with non-diabetic renal insufficiency (72.49짹11.6 years old) who survived at discharge in from The Korea Working Group on Myocardial Infarction (KorMI). Renal insufficiency was defined as GFR<60mL/min/1.73m2 calculated by the Modification of Diet in Renal Disease(MDRD) study equation. They were divided to the two groups according to the prescription of statin at hospital discharge (Statin group; n=324, Non-statin group; n=933). The primary end point was the composite of 1-year major adverse cardiac events including death, recurrent myocardial infarction (MI), target vessel revascularization and coronary artery bypass grafting. Results: Statin group were likely to have higher GFR (41.17 vs. 45.33, p<0.001), left ventricular ejection fraction. In the laboratory finding, statin group had higher serum levels of total cholesterol, triglyceride, lower density lipoprotein cholesterol, and high sensitive C-reactive protein(CRP) and lower creatinine and N-terminal pro B-type natriuretic peptide(NT pro-BNP). Statin therapy was not significantly reduced the risk of the composite the primary end point (22.7% vs. 16.5%, p=0.104) with no difference in cardiac death, non-cardiac death, MI and revascularization. In multivariate analysis, statin therapy was not the favorable prognostic factor in AMI patients with non-diabetic renal insufficiency. Conclusions: In AMI patients with non-diabetic renal insufficiency, statin therapy seemed to have no additional benefit. However, further randomized trials are needed.